At Clasp we are committed to translating cutting-edge research into meaningful medicines for patients. We merge a deep understanding of cancer genetics with extensive experience growing successful clinical-stage immuno-oncology companies to develop meaningful innovations for people suffering from cancer.

This connection is exemplified by their name and their logo, which evokes the links Clasp is forging between cells and its partnership with those who are central to their mission. Our work together attracted tremendous media interest, amplifying the Clasp team’s key messages and boosting awareness of its $150 million Series A financing.

Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver...

Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers.

2024年3月21日 · Clasp专注于开发针对每例患者免疫系统量身定制的模块化T细胞接合器，这些TCE为现货型、双特异性抗体样分子，旨在同时靶向T细胞表面的CD3蛋白与癌细胞表面的肿瘤特异性突变肽，以促进T细胞对癌细胞的攻击。

2024年3月20日 · Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type.

2024年11月7日 · Clasp的平台可识别突变相关的新抗原，并开发可选择性结合源自这些致癌驱动因素的HLA（人类白细胞抗原）呈递肽的TCE。 These innovative pHLAreTM molecules, precise HLA redirecting engagers, direct all T cell types to destroy the tumor.

Clasp targets mutated protein fragments, or peptides, that are displayed by specialized HLA molecules on the surfaces of cancer cells. This approach opens up the possibility of targeting the vast majority of cancer-driving proteins that are expressed exclusively inside the cell, and thus invisible to traditional antibody-like drugs.

Using their patented MANA-SRM and MANAFEST technology, Clasp Therapeutics is able to identify mutation-associated neoantigens (MANAs) that are presented on the cell surface. They can then screen antibodies and T cell receptors against these targets to identify effective biologic or cell therapeutic interventions.

2024年3月24日 · Clasp Therapeutics是一家总部位于美国马萨诸塞州的生物技术公司，致力于开发针对每位患者免疫系统的模块化T细胞诱导体（TCE），这些TCE针对常见的致癌驱动基因突变，可制成类似抗体的现成药物，专门针对各种难以治疗的肿瘤类型，为免疫肿瘤学带来了更高的 ...